

Wellnex Life Signs Supply Agreement in Australia and New Zealand with GlaxoSmithKline

- Wellnex Life signs a Supply Agreement with GlaxoSmithKline Consumer Trading Services Limited (GSK CTS) for the supply in Australia and New Zealand of its existing soft gel liquid analgesic, for a minimum term of three years.
- GSK Consumer Healthcare is one of the world's largest and leading global consumer healthcare companies
- Wellnex Life will license and supply its innovative paracetamol soft gel liquid analgesic product to GSK.
- This highlights the Company's business model of bringing innovative and in-demand products to market in a capital-efficient way.

Wellnex Life Limited (ASX: WNX) (the Company or WNX) is pleased to announce it has signed a Supply Agreement (Agreement) with GSK CTS (a subsidiary of GSK Consumer Healthcare). Under the Agreement, Wellnex Life will supply its innovative soft gel liquid paracetamol to GSK CTS for it to be retailed in Australia and New Zealand under GSK Consumer Healthcare's pain relief brand. The term of the Agreement is for a minimum of three years. Wellnex Life will also be responsible for the manufacture of the products for GSK CTS.

GSK Consumer Healthcare is a world-leading consumer healthcare company. They combine science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend including Panadol, Sensodyne, Voltaren, Polident, Centrum, Otrivin and Advil

This opportunity highlights Wellnex Life's business model of bringing innovative health and wellness products first or fast to the market. This model allows Wellnex Life to supply its innovative product under a trusted brand and enables the Company to secure valuable agreements with leading partners, such as GSK Consumer Healthcare.

Zack Bozinovski, Director of Wellnex Life, said: "We are excited to announce that Wellnex Life has signed a new supply agreement with a subsidiary of a leading healthcare company GSK Consumer Healthcare. Under the agreement, we will provide our soft gel liquid paracetamol to GSK CTS for supply in Australia and New Zealand under their pain relief brand. We're pleased to be able to partner

with leading companies to get products on shelves and are excited to work with GSK Consumer Healthcare.”

George Karafotias, CEO of Wellnex Life, said: “This agreement with a subsidiary of GSK Consumer Healthcare is a testament to the team at Wellnex Life and specifically Brand Solutions Australia. Brand Solutions Australia has been working with GSK Consumer Healthcare for over 12 months to secure this agreement and was one of the compelling reasons for the acquisition of BSA.”

Join a briefing

Wellnex Life would like to invite investors to a briefing at 12pm (AEDT) on Tuesday 22nd March to provide a company update and discuss the agreement and its significance in more detail.

Visit this page to register: <https://wellnexlife.investorportal.com.au/live-investor-briefing/>

This announcement has been authorised for release on the ASX by the Company's Board of Directors.

ENDS

Further Information:

Company:

George Karafotias
Chief Executive Officer
Email: george.k@wellnexlife.com.au
Phone: 03 8399 9419

Investor Relations and Media:

Sophie Bradley
Investor Relations Executive
Email: IR@reachmarkets.com.au
Phone: 0450 423 331

About Wellnex Life

Wellnex Life (ASX: WNX) is an Australian brand and distribution company of customer-focused health and wellness products. The company's large portfolio, first-to-market strategy and established retail distribution network provide an attractive business model for growth and profitability. Wellnex's mission is to deliver health, wellness, and vitality solutions to consumers in Australia and worldwide.

Stay updated

To stay updated with the latest company news and announcements, update your details on the [Wellnex Life investor centre](#).